IRIS
MESSINA, Sonia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.701
NA - Nord America 10.043
AS - Asia 6.953
SA - Sud America 3.041
AF - Africa 224
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 15
AN - Antartide 1
Totale 32.997
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.803
RU - Federazione Russa 6.603
SG - Singapore 2.893
BR - Brasile 2.624
CN - Cina 1.948
IE - Irlanda 1.674
SE - Svezia 997
IT - Italia 743
HK - Hong Kong 730
DE - Germania 529
VN - Vietnam 486
PL - Polonia 477
FR - Francia 457
FI - Finlandia 365
UA - Ucraina 350
GB - Regno Unito 256
IN - India 202
AR - Argentina 156
BD - Bangladesh 100
MX - Messico 100
IQ - Iraq 79
TR - Turchia 78
CA - Canada 76
EC - Ecuador 74
ID - Indonesia 64
ZA - Sudafrica 64
AT - Austria 51
MA - Marocco 45
UZ - Uzbekistan 45
VE - Venezuela 45
NL - Olanda 44
BE - Belgio 41
PK - Pakistan 39
CO - Colombia 38
JP - Giappone 38
PY - Paraguay 31
CL - Cile 26
KE - Kenya 26
CI - Costa d'Avorio 24
ES - Italia 23
TN - Tunisia 22
PE - Perù 20
PH - Filippine 20
JO - Giordania 19
IL - Israele 18
SA - Arabia Saudita 18
AE - Emirati Arabi Uniti 17
UY - Uruguay 17
AZ - Azerbaigian 16
CZ - Repubblica Ceca 16
KZ - Kazakistan 16
NP - Nepal 16
CR - Costa Rica 15
EG - Egitto 15
MY - Malesia 15
IR - Iran 12
LT - Lituania 12
OM - Oman 12
PA - Panama 12
DO - Repubblica Dominicana 11
EU - Europa 11
NZ - Nuova Zelanda 10
PS - Palestinian Territory 10
AU - Australia 9
DZ - Algeria 9
JM - Giamaica 9
LB - Libano 9
AL - Albania 8
BO - Bolivia 8
KW - Kuwait 7
RS - Serbia 7
AO - Angola 6
HN - Honduras 6
PT - Portogallo 6
RO - Romania 6
HU - Ungheria 5
KR - Corea 5
LK - Sri Lanka 5
NI - Nicaragua 5
QA - Qatar 5
CY - Cipro 4
HR - Croazia 4
SK - Slovacchia (Repubblica Slovacca) 4
XK - ???statistics.table.value.countryCode.XK??? 4
BG - Bulgaria 3
BH - Bahrain 3
BY - Bielorussia 3
GE - Georgia 3
NG - Nigeria 3
SN - Senegal 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
TW - Taiwan 3
AM - Armenia 2
CH - Svizzera 2
GA - Gabon 2
GR - Grecia 2
GY - Guiana 2
KG - Kirghizistan 2
KH - Cambogia 2
Totale 32.966
Salva come PNG Salva come JPEG
Città #
Moscow 2.091
Dublin 1.668
Singapore 1.492
Ashburn 1.392
Dallas 1.128
Chandler 1.055
Jacksonville 794
Hong Kong 730
Beijing 723
Nyköping 568
Warsaw 460
The Dalles 402
Princeton 363
Medford 307
Lauterbourg 283
Cambridge 260
San Jose 256
Los Angeles 235
Des Moines 219
Ann Arbor 210
Messina 188
Dearborn 182
São Paulo 173
Ho Chi Minh City 157
Boardman 147
Buffalo 145
Munich 126
New York 101
San Mateo 94
Lancaster 92
Hanoi 90
Tianjin 89
Redondo Beach 88
Rio de Janeiro 78
Shenyang 75
Jinan 71
Wilmington 71
Pune 70
Rome 69
Bremen 67
Turku 64
Guangzhou 61
Belo Horizonte 57
Council Bluffs 57
Frankfurt am Main 54
Nanjing 53
Brasília 52
Houston 50
Orem 47
Curitiba 46
Porto Alegre 46
Woodbridge 45
Tashkent 43
Baghdad 38
Brussels 38
Dong Ket 38
Nuremberg 37
Hangzhou 36
Chennai 35
Tokyo 35
Brooklyn 33
Campinas 33
Zhengzhou 33
Guarulhos 32
Hebei 32
Ningbo 32
Santa Clara 29
Shanghai 28
Vienna 28
Johannesburg 27
Ribeirão Preto 26
Guayaquil 25
Helsinki 25
Jakarta 25
Quito 25
Seattle 25
Abidjan 24
Atlanta 24
Amsterdam 23
Haikou 23
Taizhou 22
Lappeenranta 21
Stockholm 21
Toronto 21
London 20
Mexico City 20
Milan 20
Nairobi 20
Nanchang 20
Salvador 20
Sorocaba 20
São José do Rio Preto 20
Changsha 19
Fortaleza 19
Joinville 19
Juiz de Fora 19
Norwalk 19
San Francisco 19
Shenzhen 19
Asunción 18
Totale 18.689
Salva come PNG Salva come JPEG
Nome #
A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy 245
A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript “single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1” written by pechmann and colleagues” 222
24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. 205
Which are the factors influencing NIV adaptation and tolerance in ALS patients? 198
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 197
Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice 193
A new form of alpha-dystroglycanopathy associated with severe drug-resistant epilepsy and unusual EEG features 191
Alexithymia, burden and resilience in ALS’ caregivers 189
Antiosteoporotic activity of genistein aglycone in postmenopausal women: Evidence from a post-hoc analysis of a multicenter randomized controlled trial 186
Hippo signaling pathway is altered in Duchenne muscular dystrophy 186
Effect of exercise on telomere length and telomere proteins expression in mdx mice 186
Autonomic nervous system involvement in spinal muscular atrophy. 184
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 184
Nusinersen versus sham control in later-onset spinal muscular atrophy 182
ANT1 is reduced in sporadic inclusion body myositis. 175
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 173
Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy 173
Myasthenia Gravis: Unusual Presentations and Diagnostic Pitfalls 173
Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center 173
6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes 168
Pilot study of flavocoxid in ambulant DMD patients. 167
Pilot study of serial casting in muscular dystrophy patients. 165
Neuropsychological patter in centronuclear myopathy due to DNM2 gene mutations. 165
Apoptosis and apoptosis-related proteins in thyroid myopathies 164
Pilot study of serial casting of ankles in muscular dystrophy patients. 164
Modulation of neural nitric oxide synthase by the isoflavone genistein promotes muscle regeneration in mdx mice 163
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 162
An observational study of functional abilities in infants, children, and adults with type 1 SMA 159
Predictors of adaptation to non-invasive ventilation in amyotrophic lateral sclerosis 158
Functional changes in Duchenne muscular dystrophy: A 12-month longitudinal cohort study. 156
Parenteral nutrition improves nutritional status, autonomic symptoms and qol in patients with TTR-FAP 156
Emotional burden and coping strategies in amyotrophic lateral sclerosis caregivers: The role of metacognitions 154
Clinical and muscle magnetic resonance imaging study of an Italian family with autosomal dominant inclusion body myopathy not linked to known genetic loci 153
Predictors of adaptation to non-invasive ventilation in neuromuscular disorders. 152
Psycological status and emotional burden in amyotrophic lateral sclerosis caregivers: the role of metacognitive processes. 152
Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates 152
The 24-month PUL changes and steroids correlation. 151
Impaired myocardial deformation revealing subclinical left ventricular dysfunction in children with Duchenne dystrophy: a speckle tracking echocardiography study 151
Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis 151
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 151
ALS Cognitive Behavioral Screen (ALS-CBS): normative values for the Italian population and clinical usability 151
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 151
A comprehensive molecular approach in COLA6 related myopathies based on genomic sequencing, transcriptional analysis and array CGH. 150
Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis 150
Pilot study of flavocoxid in ambulant DMD patients. 149
Outcome measures in Duchenne muscular dystrophy: validation of the Pediatric Quality of Life InventoryTM Neuromuscular Module in the Italian population and correlation with other functional assessments. 149
Pilot study of flavocoxid in ambulant DMD patients. 149
Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age 149
Genomic Variations Affecting Biological Effects of Statins 148
BONE INVOLVEMENT IN DUCHENNE MUSCULAR DYSTROPHY 148
Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance 147
24-Holter ECG in type II and III SMA 146
Novel outcome measures for Charcot-Marie-Tooth disease: Validation and reliability of the 6-min walk test and StepWatch™ Activity Monitor and identification of the walking features related to higher quality of life 146
Severe rhabdomyolysis in a patient with “Heat Stroke” 146
Burden, social network and professional support in the families of patients with muscular dystrophies: results from the GUP10002 study. 144
Burden, professional support, and social network in families of children and young adults with muscular dystrophies 143
The 6-min walk test as a new outcome measure in Amyotrophic lateral sclerosis 143
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 142
Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis 141
TBK1 is associated with ALS and ALS-FTD in Sardinian patients 140
Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes 139
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 139
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 139
Cardiac function in types II and III spinal muscular atrophy: should we change standards of care? 139
Development of an academic disease registry for spinal muscular atrophy 139
Clinical variability in spinal muscular atrophy type III 139
Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy 139
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report. 138
Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy 137
Conceptualizing the relations between metacognition and executive functions in Amyotrophic Lateral Sclerosis (ALS) patients’ caregivers. A preliminary study 136
Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report 136
Sport activity in Charcot-Marie-Tooth disease: A case study of a Paralympic swimmer 135
Clinical and genetic spectrum in a large cohort of patients with a genetic diagnosis of Congenital Muscular Dystrophies in the UK and differences with the Italian population 135
Teriparatide (rhPTH) treatment in Duchenne Muscular Dystrophy, a case report. 135
Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data 135
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report 134
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 134
Selective short-term verbal memory involvement in two siblings carrying centronuclear myopathy due to DNM2 gene mutations 133
Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions 131
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 131
6 min walking test 12 month changes in DMD: Correlation with genotype. 129
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle 129
Expression of the trascription factor NFkB in different muscular dystrophies 128
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with neuromuscolar disorders: a speckle tracking study 128
Implication of SIRT1 and its downstream pathways in dystrophic process. 128
A very late onset AChR and MuSK double positive myasthenia gravis: a case description and literature review 127
study of flavocoxid in ambulant DMD patients. 127
Dyscondrosteosis in a child with Becker muscular dystrophy: an unreported association between Xp21 gene (DMD/BMD) deletion and a novel homozygous SHOX gene mutation 126
The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability. 126
Bone quality in Duchenne muscular dystrophy 126
Histological effects of givinostat in boys with Duchenne muscular dystrophy 125
Timed rise from floor as a predictor of disease progression in Duchenne muscular dystrophy: An observational study 125
Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs 125
Clinical and genetic spectrum in a large cohort of patients with a genetic diagnosis of Congenital Muscular Dystrophies: Analysis of the UK diagnostic service 2001-2013. 122
Telomere shortening and telomere associated proteins in exercised wild type and mdx mice. 121
Muscle Fat-Fraction and Mapping in Duchenne Muscular Dystrophy: Evaluation of Disease Distribution and Correlation with Clinical Assessments: A preliminary experience. 118
Pilot study of flavocoxid in ambulant DMD patients. 118
The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-α activation and ameliorates muscle function and morphology in mdx mice. 118
Dual-echo dual flip angle gradient-echo MRI technique for quantification of muscle fat fraction in Duchenne muscular dystrophy: a new valuable outcome measure. 117
NF-kB blockade reduces skeletal muscle degeneration and enhances muscle function in mdx mice. 116
Totale 15.063
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.398
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.398
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021396 0 0 0 0 0 0 0 0 0 200 106 90
2021/20221.688 9 123 13 113 97 14 125 71 51 116 211 745
2022/20234.386 391 318 161 309 379 382 29 236 1.999 21 122 39
2023/20241.108 84 200 73 100 112 214 46 31 16 43 28 161
2024/20255.731 98 76 102 350 246 151 161 1.365 1.509 327 431 915
2025/202615.530 694 1.196 1.308 1.300 1.184 3.515 1.894 1.877 1.907 655 0 0
Totale 33.607